Stocks
GlaxoSmithKline (GSK) R&D US GAAP (year values) |
|||||||||
| 2022 | 2022 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D, £ | 5 488 000 000 | 5 488 000 000 | 5 488 000 000 | 6 221 000 000 | 6 223 000 000 | 5 719 000 000 | |||
| Changes by years, y/y, % | +4% | 0% | 0% | +13% | +0% | +9.8% | |||
GlaxoSmithKline. R&D, £
GlaxoSmithKline. R&D, changes, %
GlaxoSmithKline. R&D, sum by quarters, £
GlaxoSmithKline (GSK) R&D US GAAP (quarter values) |
||||||||
| 2024Q1 | 2024Q2 | 2024Q2 | 2024Q3 | 2024Q3 | LTM ? | |||
| R&D, £ | 1 373 000 000 | 1 428 000 000 | 1 428 000 000 | 1 459 000 000 | 1 459 000 000 | 5 719 000 000 | ||
| Changes by years, y/y, % | +9% | +6% | +6% | -7% | -7% | |||
| Changes by quarters, q/q, % | -33% | +4% | 0% | +2% | 0% | |||
